Japanese drugmaker under scrutiny for 76 deaths linked to red yeast rice supplements

In a troubling development, Japanese pharmaceutical company Kobayashi Pharmaceutical is under intense scrutiny as it investigates 76 additional deaths potentially linked to its red yeast rice dietary supplements. This update follows an earlier confirmation in March of five fatalities associated with the “beni-koji choleste help” supplements, a figure recently corrected to four after one case was found to be unrelated, according to Kyodo News.

The company’s failure to promptly report these incidents to government authorities has drawn sharp criticism. Health, Labour and Welfare Minister Keizo Takemi expressed deep regret over the company’s handling of the situation, emphasizing the urgency and seriousness of the matter. “It is extremely regrettable that the company did not report the updated number of suspected deaths to the ministry since March,” Takemi stated.

Takemi announced that the health ministry will now take an active role in the investigation, ensuring transparency and regular updates to the public. “We cannot leave Kobayashi Pharmaceutical alone to handle it anymore,” he declared.

In response to the escalating crisis, the health ministry has mandated Kobayashi Pharmaceutical to submit a comprehensive investigation plan by Saturday. This plan must address the suspected 76 deaths and outline steps to mitigate health risks to families and medical institutions involved.

As the investigation unfolds, the scandal continues to impact the reputation of Kobayashi Pharmaceutical and raises broader concerns about the safety and regulation of dietary supplements in Japan.